Published in Drugs Exp Clin Res on January 01, 1998
Effects of resveratrol in inflammatory arthritis. Inflammation (2007) 1.34
Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence. Curr Pharm Des (2013) 1.22
Neuroprotective abilities of resveratrol and other red wine constituents against nitric oxide-related toxicity in cultured hippocampal neurons. Br J Pharmacol (2000) 1.20
Resveratrol-induced gene expression profiles in human prostate cancer cells. Cancer Epidemiol Biomarkers Prev (2005) 1.05
Chondroprotective effects and mechanisms of resveratrol in advanced glycation end products-stimulated chondrocytes. Arthritis Res Ther (2010) 0.98
Cyclodextrin-based nanosponges for delivery of resveratrol: in vitro characterisation, stability, cytotoxicity and permeation study. AAPS PharmSciTech (2011) 0.90
Suppression of human monocyte tissue factor induction by red wine phenolics and synthetic derivatives of resveratrol. Thromb Res (2006) 0.89
Inhibition of cardiac voltage-gated sodium channels by grape polyphenols. Br J Pharmacol (2006) 0.87
Phytoestrogens: food or drug? Clin Cases Miner Bone Metab (2007) 0.82
Specific Conditions for Resveratrol Neuroprotection against Ethanol-Induced Toxicity. J Toxicol (2012) 0.79
The effect and action mechanism of resveratrol on the vascular endothelial cell by high glucose treatment. Saudi J Biol Sci (2015) 0.79
Delphinidin-3-glucoside protects against oxidized low-density lipoprotein-induced mitochondrial dysfunction in vascular endothelial cells via the sodium-dependent glucose transporter SGLT1. PLoS One (2013) 0.77
Effects of resveratrol supplementation on bone growth in young rats and microarchitecture and remodeling in ageing rats. Nutrients (2014) 0.77
Effect of Resveratrol and Nicotine on PON1 Gene Expression: In Vitro Study. Indian J Clin Biochem (2013) 0.75
Resveratrol enhances polyubiquitination-mediated ARV7 degradation in prostate cancer cells. Oncotarget (2017) 0.75
The red wine antioxidant resveratrol protects isolated rat hearts from ischemia reperfusion injury. Free Radic Biol Med (1999) 1.56
Antiplatelet activity of synthetic and natural resveratrol in red wine. Int J Tissue React (1995) 1.32
Cardioprotection of red wine: role of polyphenolic antioxidants. Drugs Exp Clin Res (1999) 1.28
Effects of resveratrol on the rat brain respiratory chain. Drugs Exp Clin Res (1999) 1.26
Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application. Curr Drug Metab (2007) 1.26
Resveratrol, a polyphenol found in wine, reduces ischemia reperfusion injury in rat kidneys. J Cardiovasc Pharmacol (2001) 1.19
Effects of 1,25(OH)2D3 in experimental mesangial proliferative nephritis in rats. Kidney Int (2001) 1.17
Myocardial protection with red wine extract. J Cardiovasc Pharmacol (2000) 1.14
C reactive protein in patients with chronic renal diseases. Ren Fail (2001) 1.10
Calcitriol modulates in vivo and in vitro cytokine production: a role for intracellular calcium. Kidney Int (1998) 1.05
Treatment with 1,25-dihydroxyvitamin D3 preserves glomerular slit diaphragm-associated protein expression in experimental glomerulonephritis. Int J Immunopathol Pharmacol (2006) 1.01
Plasma, urine and tissue levels of trans- and cis-resveratrol (3,4',5-trihydroxystilbene) after short-term or prolonged administration of red wine to rats. Int J Tissue React (1996) 1.00
Activity in vitro of resveratrol on granulocyte and monocyte adhesion to endothelium. Am J Clin Nutr (1998) 1.00
Reactive oxygen metabolites and prooxidant status in children with Down's syndrome. Int J Clin Pharmacol Res (2001) 0.99
Anti-apoptotic effect of trans-resveratrol on paclitaxel-induced apoptosis in the human neuroblastoma SH-SY5Y cell line. Neurosci Lett (2001) 0.96
Selective anti-leukaemic activity of low-dose histone deacetylase inhibitor ITF2357 on AML1/ETO-positive cells. Oncogene (2007) 0.96
Antiplatelet activity of cis-resveratrol. Drugs Exp Clin Res (1996) 0.93
A novel recessive mutation of fibroblast growth factor-23 in tumoral calcinosis. J Bone Joint Surg Am (2009) 0.93
Bone health and aldosterone excess. Osteoporos Int (2013) 0.92
Resveratrol-induced activation of the mitogen-activated protein kinases, ERK1 and ERK2, in human neuroblastoma SH-SY5Y cells. Neurosci Lett (1999) 0.91
Kinetics of trans- and cis-resveratrol (3,4',5-trihydroxystilbene) after red wine oral administration in rats. Int J Clin Pharmacol Res (1996) 0.91
Effect of increasing doses of lisinopril on proteinuria of normotensive patients with IgA nephropathy and normal renal function. Int J Clin Pharmacol Res (1994) 0.91
Efficacy of propafenone in paramyotonia congenita. Neurology (2007) 0.90
1,25-dihydroxyvitamin D(3) dose-dependently inhibits LPS-induced cytokines production in PBMC modulating intracellular calcium. Transplant Proc (2001) 0.90
The link of biocompatibility to cytokine production. Kidney Int Suppl (2000) 0.89
FokI polymorphism of the vitamin D receptor gene correlates with parameters of bone mass and turnover in a female population of the Italian island of Lampedusa. Calcif Tissue Int (2006) 0.88
Does resveratrol induce pharmacological preconditioning? Int J Tissue React (2000) 0.85
The therapeutic potential of Aloe Vera in tumor-bearing rats. Int J Tissue React (1998) 0.84
Band diagram of spin waves in a two-dimensional magnonic crystal. Phys Rev Lett (2011) 0.84
A comparison of methods for the analysis of low abundance proteins in desmoid tumor cells. Anal Biochem (2006) 0.83
Evaluation of kinetic parameters of natural phytoalexin in resveratrol orally administered in wine to rats. Drugs Exp Clin Res (1998) 0.83
Soy allergy is not common in atopic children: a multicenter study. Pediatr Allergy Immunol (1997) 0.82
Regioselective synthesis and biological profiling of butyric and phenylalkylcarboxylic esters derivated from D-mannose and xylitol: influence of alkyl chain length on acute toxicity. Eur J Pharm Sci (1999) 0.81
Toxic effects on rabbit kidney cell cultures of a new aminoglycoside. Drugs Exp Clin Res (1987) 0.81
Metabolic fate of exogenous chondroitin sulfate in the experimental animal. Arzneimittelforschung (1990) 0.81
Role of endothelin-1 in carrageenin-induced inflammation. Int J Tissue React (1992) 0.81
Growth hormone deficiency in the transition period: body composition and gonad function. J Endocrinol Invest (2011) 0.81
Protective action of L-carnitine and coenzyme Q10 against hepatic triglyceride infiltration induced by hyperbaric oxygen and ethanol. Drugs Exp Clin Res (1993) 0.81
Protective effect of L-propionylcarnitine on cyclosporine-induced nephrotoxicity. Drugs Exp Clin Res (1995) 0.80
C-reactive protein as a marker of chronic inflammation in uremic patients. Blood Purif (2000) 0.80
Stability of resveratrol over time and in the various stages of grape transformation. Drugs Exp Clin Res (1998) 0.79
Sucralfate modulates uPAR and EGFR expression in an experimental rat model of cervicitis. Int J Immunopathol Pharmacol (2008) 0.79
ANCA in dialysis patients: a role for bioincompatibility? Int J Artif Organs (2000) 0.79
Relationship of volumetric bone mineral density and structural parameters with ERalpha gene polymorphisms. Calcif Tissue Int (2007) 0.79
Maturation and apoptosis of primary human acute myeloblastic leukemia cells are determined by TNF-alpha exclusively through CD120A stimulation. Haematologica (1999) 0.79
Thrombosis induced by endothelin (ET-1) and carrageenin in rats treated with indomethacin and propionyl carnitine. Drugs Exp Clin Res (1993) 0.78
Apoptotic and antiproliferative effects of gemcitabine and gemcitabine plus Ara-C on blast cells from patients with blast crisis chronic myeloproliferative disorders. Haematologica (1997) 0.78
Calcitriol oral therapy for the prevention of secondary hyperparathyroidism in patients with predialytic renal failure. Clin Nephrol (1998) 0.78
Phytoalexin resveratrol (3-4'-5-trihydroxystilbene) modulates granulocyte and monocyte endothelial adhesion. Transplant Proc (1998) 0.78
Immunomodulatory activity of shikimic acid and quercitin in comparison with oseltamivir (Tamiflu) in an in vitro model. J Med Virol (2008) 0.78
Benzo[a]pyrene diol-epoxide DNA adducts and levels of polycyclic aromatic hydrocarbons in autoptic samples from human lungs. Chem Biol Interact (1998) 0.78
L-propionyl carnitine protects erythrocytes and low density lipoproteins against peroxidation. Drugs Exp Clin Res (1994) 0.77
Nitric oxide-dependent renal vasodilatation is not altered in rat with rHuEpo-induced hypertension. Kidney Blood Press Res (1999) 0.77
In vivo inhibition of TNFalpha-induced vascular permeability by resveratrol. Transplant Proc (2001) 0.77
Effect of some white wine phenols in preventing inflammatory cytokine release. Drugs Exp Clin Res (2002) 0.77
Circulating adrenomedullin is increased in preterm newborns developing intraventricular hemorrhage. Pediatr Res (2001) 0.77
Cognitive functioning self-assessment scale (CFSS): preliminary psychometric data. Psychol Health Med (2011) 0.77
Critical evaluation of endothelins assay. Int J Tissue React (1994) 0.77
Biocompatibility evaluation of polyamide hemofiltration. Int J Artif Organs (1998) 0.77
Searching for the magic bullet against cancer: the butyrate saga. Leuk Lymphoma (2001) 0.76
Human Preosteoblastic Cell Culture from a Patient with Severe Tumoral Calcinosis-Hyperphosphatemia Due to a New GALNT3 Gene Mutation: Study of In Vitro Mineralization. Calcif Tissue Int (2015) 0.76
Comparative histochemical study of adriamycin and adriamycinol in rat liver and heart. In Vivo (1992) 0.76
Wine, sirtuins and nephroprotection: not only resveratrol. Med Hypotheses (2010) 0.76
Butyrate-stable monosaccharide derivatives induce maturation and apoptosis in human acute myeloid leukaemia cells. Br J Haematol (1998) 0.76
Cyclosporine-induced lipid peroxidation and propionyl carnitine protective effect. Int J Tissue React (1999) 0.76
Protective role of propionyl carnitine in vascular disorders experimentally induced by endothelin (ET-1) serotonin and K-carrageenin. Drugs Exp Clin Res (1993) 0.76
Comparative effects of gentamicin, amikacin and dactimicin on excretion of N-acetyl-beta-D-glucosaminidase (NAG) and kidney histological pattern in rats. Drugs Exp Clin Res (1987) 0.75
Fluorescence in sections of cardiac muscle from rats acutely treated with 4'-0-tetrahydropyranil-adriamycin hydrochloride (THP). Drugs Exp Clin Res (1985) 0.75
Characterization of the functional and growth properties of long-term cell cultures established from a human somatostatinoma. Endocr Relat Cancer (2006) 0.75
Conformational effects on the activity of drugs. 10. Synthesis, conformation, and pharmacological properties of 1-(2,5-dimethoxyphenyl)-2-aminoethanols and their morpholine analogues. J Med Chem (1983) 0.75
Protective synergic effect of coenzyme Q10 and carnitine on hyperbaric oxygen toxicity. Int J Tissue React (1990) 0.75
Experimental comparative renal toxicity of lithium and rubidium. Drugs Exp Clin Res (1985) 0.75
Protective action of propionyl-L-carnitine on toxicity induced by hyperbaric oxygen. Drugs Exp Clin Res (1990) 0.75
Synergic and complementary effects of L-carnitine and coenzyme Q on long-chain fatty acid metabolism and on protection against anthracycline damage. Int J Tissue React (1990) 0.75
Protection of adenylate pool and energy charge by L-carnitine and coenzyme Q during energy depletion in rat heart slices. Int J Tissue React (1990) 0.75
PAF-induced histamine release in the isolated perfused rat kidney. Int J Tissue React (1988) 0.75
Cyclovinylogues of some antimuscarinic drugs. Arch Pharm (Weinheim) (1985) 0.75
Evaluation and comparison of radioimmunoassay methods using monoclonal or polyclonal antibodies for the assay of cyclosporine in blood samples. Int J Tissue React (1989) 0.75
[Behavior of the renin-aldosterone system in a case of pheochromocytoma]. Minerva Pediatr (1982) 0.75
Comparative nephrotoxicity and tissue accumulation of dactimicin, amikacin and gentamicin. Drugs Exp Clin Res (1987) 0.75
Aclacinomycin tissue distribution in the rat. Chemioterapia (1988) 0.75
Effects of bisphosphonates on cells of the mononuclear phagocyte system. Acta Physiol Hung (1990) 0.75
Excretion of aminoglycosides in a rat kidney model. Drugs Exp Clin Res (1989) 0.75
Tissue concentrations of coenzyme Q in liver of rats intoxicated by carbon tetrachloride. Int J Tissue React (1986) 0.75
Plasma and tissue concentrations of coenzyme Q10 in the rat after its oral administration. Int J Tissue React (1988) 0.75
Protective action of coenzyme A on paracetamol-induced tissue depletion of glutathione. Int J Tissue React (1990) 0.75
Plasma and tissue concentrations of coenzyme Q10 in the rat after intravenous administration by a microsphere delivery system or in a new type of solution. Int J Tissue React (1988) 0.75
Enzymuria in aminoglycoside-induced kidney damage. Comparative study of gentamicin, amikacin, sisomicin and netilmicin. Int J Clin Pharmacol Res (1985) 0.75
Plasma and tissue concentrations of coenzyme Q10 in the rat after intravenous, oral and topical administrations. Int J Tissue React (1990) 0.75
Autoradiographic distribution study of 14C-amphetamine in pregnant mice and newborns. J Nucl Med Allied Sci (1985) 0.75
Hyperbaric oxygen- and ethanol-induced infiltration of rat hepatic triglycerides and the protective action of coenzyme A. Int J Tissue React (1990) 0.75
Adriamycin, aclacinomycin and thepirubicin intracardiac distribution examined by fluorescence microscopy. Chemioterapia (1988) 0.75